Robin L. Smith, M.D., MBA Chairman & CEO of Neostem (NYSE: NBS)

Uploaded on Friday 7 December 2012


NeoStem, continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift occurring in medicine. We anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy industry. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, PCT, with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe that, with our expertise and research capabilities and collaborations, we will achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem's most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC ("Amorcyte"), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001's efficacy in preserving heart function after a heart attack. Athelos Corporation ("Athelos"), which is 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cell product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert to create a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a substantial intellectual property estate, we are well positioned to succeed.

For more information, please visit

The Vatican:
Dr. Robin Smith, CEO of NeoStem and Chairman and President of the Stem for Life Foundation, and Dr. Max Gomez, trustee of the Stem for Life Foundation presented the first copy of their book, Our Stem Cells: The Mystery of Life and Secrets of Healing … to The Holy Father, Pope Benedict XVI. This is part of an ongoing mission to advance scientific research on adult stem cell therapies and explore their cultural and ethical implications.

The book is the result of collaboration between the Vatican’s Pontifical Council for Culture via its charitable foundation STOQ. It includes a special address by His Holiness Benedict XVI, urging increased support and awareness for advancements in adult stem cell research in order to alleviate human suffering. The book focuses on concepts discussed at the First International Vatican Adult Stem Cell Conference (2011) and presents the reader with an engaging, comprehensive overview of adult stem cells and their vital role in a future of regenerative medicine.

Dr. Robin L. Smith's expertise in business development and medicine includes her extensive and diversified experience serving in executive and board level capacities for various medical enterprises and healthcare-based entities. Since 2006, Dr. Smith has served as Chairman and CEO of NeoStem, a rapidly growing company in the stem cell sector. In 2010, NeoStem earned the New Economy "Best Stem Cell Company" award. Dr. Smith has successfully led the business in completing five acquisitions as well as raising over 100 million dollars toward building one of the leading companies in the emerging cell therapy industry.

From 2000 to 2003, Dr. Smith served as President & Chief Executive Officer of IP2M, a multi-platform media company specializing in healthcare. During her term, the company was selected as being one of the 10 fastest growing technology companies in Houston, Texas. IP2M was sold to a publicly traded company in February 2003. Previously, from 1998 to 2000, Dr. Smith was Executive Vice President and Chief Medical Officer for Health Help, Inc., a National Radiology Management company that managed 14 percent of all healthcare dollars spent by large insurance companies.

Dr. Smith has acted as a senior advisor to, and investor in, both publicly traded and privately held companies where she has played a significant role in restructuring and or growing such businesses. She currently serves on the Board of Trustees of the NYU Langone Medical Center and is past Chairman of the Board of Directors for the New York University Hospital for Joint Diseases where she headed up new development efforts and board member recruitment. Dr. Smith has also served on the Board of Choose Living as well as other public and private companies. Currently, Dr. Smith is the President and serves on the Board of Directors of The Stem for Life Foundation, a non-profit entity with a goal of educating the public about the growing benefits of stem cell therapies and applications. Dr. Smith received a medical degree from Yale University in 1992 and a master's degree in business administration from the Wharton School at the University of Pennsylvania in 1997.

Dr. Max Gomez, Ph. D. is a native of Havana, Cuba and was the medical correspondent/senior health editor for the NBC flagship television station WNBC in New York City. He delivered segments on health, science and medicine on the 5pm news.


Language: English

Length: 4:12

Country: United States

Creative Commons License

Robin L. Smith, M.D., MBA Chairman & CEO of Neostem (NYSE: NBS) by bitLanders is licensed under a Creative Commons Attribution 3.0 License.